Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed Growth (3y) (2017 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 4,853.00 |
| 10 | Viridian Therapeutics, Inc.\DE | 651.67 Mn | 651.67 Mn | - | -123.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -123.00 |
| Dec 31, 2025 | -2,123.00 |
| Sep 30, 2025 | -2,119.00 |
| Jun 30, 2025 | -168.00 |
| Mar 31, 2025 | -181.00 |
| Dec 31, 2024 | -206.00 |
| Sep 30, 2024 | 4,651.00 |
| Jun 30, 2024 | 8,391.00 |
| Mar 31, 2024 | 6,478.00 |
| Dec 31, 2023 | 8,822.00 |
| Sep 30, 2023 | 12,868.00 |
| Jun 30, 2023 | 16,477.00 |
| Mar 31, 2023 | 23,076.00 |
| Sep 30, 2022 | 18,296.00 |
| Jun 30, 2022 | 5,816.00 |
| Mar 31, 2022 | 2,623.00 |
| Dec 31, 2021 | 1,110.00 |
| Sep 30, 2021 | -5,087.00 |
| Jun 30, 2021 | -9,572.00 |
| Mar 31, 2021 | -7,239.00 |